Navigation Links
Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders
Date:12/6/2008

ituximab plus dexamethasone.

The primary objective of the study was to compare the sustained response (platelet counts greater than or equal to 50 x 10^9/L from one month to six months from the beginning of therapy) between the two treatment groups. Secondary objectives included overall safety, initial response (platelet count of 50 x 10^9/L after 30 days of treatment), activity of the salvage therapy (dexamethasone/rituximab) in patients not responding to dexamethasone alone, the identification of clinical and laboratory factors predictive of response, and the pharmacokinetic parameters of rituximab (the level of rituximab circulating in the blood of patients during the study period) and their potential relation to response.

The researchers examined the results for all enrolled patients, regardless of whether or not they completed the study (intention-to-treat basis, ITT), and on a per-protocol (PP) basis, examining those who had completed the treatment regimen. The ITT group included 52 patients treated with dexamethasone alone and 49 treated with rituximab/dexamethasone. The PP group included 38 patients treated with dexamethasone alone and 26 treated with rituximab/dexamethasone. ITT and PP sustained response rates were 63 percent and 85 percent in the rituximab/dexamethasone combination arm as compared with 36 percent and 39 percent in the dexamethasone-alone arm.

A total of 27 patients who failed to achieve an initial or sustained response in the dexamethasone-alone arm received the salvage treatment. In this group, ITT and PP sustained response rates were 56 percent and 59 percent, respectively.

No clinical or laboratory factors predictive of a sustained response were identified in the study. There was a mild increase in the incidence of severe adverse events in the dexamethasone-plus-rituximab arm (2 percent in dexamethasone arm versus 6 percent in dexamethasone-plus-rituxima
'/>"/>

SOURCE American Society of Hematology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  As physicians ... to digital communication channels to learn about new ... finding – from a new report by global ... – shows that communicating via a customized mix ... provides the best opportunity to engage with physicians. ...
(Date:9/23/2014)... -- Enable Injections , developer of a novel ... and nearly painless for patients to self-inject large-dose biologic ... named winner of the ,Buzz of BIO Investor Forum, ... Enable is one of only two ,Buzz ... votes in the "Late Stage Leaders" category.  ...
(Date:9/23/2014)... 2014 Avillion LLP, a ... of Jarrod Longcor as Chief Business ... for structuring, negotiating and executing successful strategic alliances, ... providing management and strategic leadership to the organisation. ... team. Mr Longcor brings to Avillion ...
Breaking Medicine Technology:As sales reps see doors close for in-person visits with physicians, digital doors open communication 2As sales reps see doors close for in-person visits with physicians, digital doors open communication 3As sales reps see doors close for in-person visits with physicians, digital doors open communication 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 5Innovative Wearable Injector Developer, Enable Injections, Wins 'Buzz of BIO Investor Forum' 2Avillion Appoints Jarrod Longcor as Chief Business Officer 2
... Intra-Cellular Therapies, Inc. (ITI),today announced it has initiated ... using its drug candidate ITI-722. ITI-722 acts predominantly,as ... important new,approach to the treatment of SMI. Because ... modulatory activities, ITI believes, ITI-722 can be,used not ...
... Research Is a Winning Pursuit, WASHINGTON, Dec. ... L. Trull President, Foundation for Biomedical,Research:, Biomedical ... of pursuit" in 1980 earned Mario Capecchi a ... setback, the Harvard-educated genetics professor,persisted toward his goal. ...
Cached Medicine Technology:Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia 2Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia 3Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia 4Nobel Prize-Winning Discovery 2Nobel Prize-Winning Discovery 3
(Date:9/23/2014)... The Fit Body Boot Camp franchise is known throughout ... and their community outreach. The new Rockville Fit Body Boot ... of the company’s new fitness boot camp in ... is excited about the grand opening, because of the opportunity ... honor the memory of emergency workers who sacrificed their lives ...
(Date:9/23/2014)... 2014 Maturo Medical Weight and ... announced Dr. Lisa Maturo has received certification in ... Worldlink Medical Academy. Dr. Maturo is one of ... this credential. , World-renowned bioidentical hormone replacement ... the rigorous training course, which trained participants in ...
(Date:9/23/2014)... 23, 2014 Wohl Associates ... packaging equipment, has recently taken delivery of used industrial ... include mixers, sheeters, and equipment for producing gnocchi and ... Toresani unit and a La Parmigiana mixer/extruder. With a ... a mixing tank that is 17” wide, 28” long ...
(Date:9/23/2014)... 23, 2014 Hope For The Warriors® ... Celebration to be hosted in Boston, Massachusetts on Sunday, ... Amphitheater. This signature event honors the courage of our ... the fallen. Proceeds from the evening will benefit Hope ... a sense of self, restoring the family unit, and ...
(Date:9/23/2014)... Los Angeles, CA (PRWEB) September 23, 2014 ... launched sales funnel building software application has created a ... commotion surrounding the launch of this new software has ... published an investigative review for her readers. ... such as site design, programming and development can be ...
Breaking Medicine News(10 mins):Health News:Rockville Fit Body Boot Camp Invites Community to Fitness Boot Camp Grand Opening 2Health News:Rockville Fit Body Boot Camp Invites Community to Fitness Boot Camp Grand Opening 3Health News:Doctor Lisa Maturo of Maturo Medical Obtains Expert Certification in BioIdentical Hormone Replacement Therapy from World Link Medical 2Health News:Used Industrial Pasta Machinery Now Available at Wohl Associates 2Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Boston 2Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Boston 3Health News:ClickFunnels 2.0 – Review Of Russell Brunson’s Sales Funnel Building Software Released 2
... Group,Inc. (Amex: QGP ) (http://www.QuantumMD.com ), ... Noel J. Guillama, President &,CEO, will present at ... p.m. (Pacific) on Monday, August 18, 2008 at ... Guillama will give a 23-minute presentation regarding The ...
... a national survey,of adults, 60 percent of Hispanic American ... is the #1 fatal disease among women.,Further, nearly half ... greater than that of Caucasian women. Dania Rich-Spencer, Vice,President ... the Go,Red For Women, founded by the American Heart ...
... getting infected cells to drop their guard according to ... a catalyst to a cancer-busting reaction which calls up an ... Cancer adapts quickly to traditional drugs which attack infected cells ... of defence using ruthenium as a catalyst to a reaction ...
... School of Medicine, Fox Chase Cancer Center and ... that will speed the translation of medical and ... , As part of the agreement, the ... Translational Medicine, based at Temple, to design and ...
... Program to Increase Breast and ... Cervical Cancer Screening Rates, COLUMBIA, ... care guidance company, today announced the,launch of their Women,s Health ... to help increase the,prevention and early detection of breast and ...
... all evidence of disease in selected patients with cancer ... the first published report from an ongoing clinical trial. ... Clinical Cancer Research, (published online August 12) researchers ... targeted radiation therapy had completely controlled all signs of ...
Cached Medicine News:Health News:The Quantum Group to Present at the Noble Financial Equity Conference 2Health News:The Quantum Group to Present at the Noble Financial Equity Conference 3Health News:Temple, Fox Chase and Geisinger create Keystone Institute for Translational Medicine 2Health News:Resolution Health Introduces Women's Health and Wellness Action Campaign 2Health News:Resolution Health Introduces Women's Health and Wellness Action Campaign 3Health News:Resolution Health Introduces Women's Health and Wellness Action Campaign 4Health News:Targeted radiation therapy can control limited cancer spread 2Health News:Targeted radiation therapy can control limited cancer spread 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: